AbbVie Inc. $ABBV Holdings Trimmed by Hamlin Capital Management LLC

Hamlin Capital Management LLC trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1.3% in the 3rd quarter, Holdings Channel reports. The firm owned 728,805 shares of the company’s stock after selling 9,785 shares during the quarter. AbbVie accounts for 4.6% of Hamlin Capital Management LLC’s holdings, making the stock its 4th biggest holding. Hamlin Capital Management LLC’s holdings in AbbVie were worth $190,648,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. ACT Advisors LLC. increased its position in shares of AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after acquiring an additional 41 shares during the last quarter. Willner & Heller LLC boosted its position in AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after purchasing an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC grew its stake in AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock valued at $359,000 after purchasing an additional 43 shares during the period. Fielder Capital Group LLC increased its position in shares of AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock valued at $637,000 after purchasing an additional 43 shares during the last quarter. Finally, Guardian Wealth Advisors LLC NC raised its stake in shares of AbbVie by 0.4% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock worth $2,996,000 after purchasing an additional 43 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

Analyst Ratings Changes

ABBV has been the subject of several research reports. Morgan Stanley increased their price target on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday. HSBC raised their price target on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. BMO Capital Markets raised their target price on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Finally, Guggenheim boosted their price objective on AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $276.11.

AbbVie Trading Down 0.6%

Shares of AbbVie stock traded down $1.75 on Thursday, reaching $269.61. The stock had a trading volume of 1,794,189 shares, compared to its average volume of 6,410,183. The business’s 50 day moving average is $258.27 and its two-hundred day moving average is $235.87. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $274.94. The company has a market cap of $476.34 billion, a P/E ratio of 76.27, a price-to-earnings-growth ratio of 1.22 and a beta of 0.24.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter in the previous year, the company earned $2.97 earnings per share. AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 13.93 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations strengthen the oncology pipeline. The FDA granted two Breakthrough Therapy Designations for investigational telisotuzumab adizutecan (Temab-A/ABBV-400) in colorectal cancer and non-small cell lung cancer. The designations may accelerate development and regulatory discussions for the company’s next-generation antibody-drug conjugate. AbbVie Temab-A FDA breakthrough designations
• Positive Sentiment: Epkinly produced a significant Phase 3 result. AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The data could support broader adoption and a stronger competitive position against Roche’s Polivy. AbbVie and Genmab Epkinly Phase 3 results
• Positive Sentiment: Analysts remain constructive. Cantor Fitzgerald raised its AbbVie price target to $290 from $285 and maintained an overweight rating. HSBC has also outlined a bullish case with a $315 target, providing additional support for investor sentiment.
• Neutral Sentiment: Broader market factors may be limiting gains. Rising Treasury yields and uncertain equity-market conditions are creating pressure across stocks, even as healthcare companies benefit from defensive characteristics.
• Negative Sentiment: Dividend sustainability remains a concern. Recent commentary highlighted AbbVie’s reported payout ratio near 190%, raising questions about how comfortably earnings cover the dividend. The concern may weigh on income-focused investors, although adjusted earnings and cash flow can differ from reported net income.
• Negative Sentiment: Valuation leaves less room for disappointment. With ABBV trading near its 52-week high and at an elevated earnings multiple, investors may be taking profits or demanding stronger evidence that new medicines can offset long-term Humira-related pressures.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.